NeoStem CEO Dr. Robin L. Smith to Be Interviewed Live on Clear Channel Network’s Business Radio DFW 1190AM
Interview to Air December 5th on Clear Channel's "The Traders Network" Talk Radio Show Hosted by Michael Yorba
NEW YORK, NY–(Dec 4, 2013) – NeoStem, Inc. (NASDAQ: NBS) (“NeoStem”) a leader in the emerging cellular therapy industry, today announced that Dr. Robin L. Smith, Chairman and CEO, will be interviewed live tomorrow December 5, 2013 at 3:15pm EST/2:15pm CST on Clear Channel’s business talk radio show “The Traders Network” hosted by Michael Yorba.
Tune into the live broadcast on Clear Channel’s iHeart Radio feed by clicking on the link below. There will be an archive available streamed shortly after the interview.
Live Link: http://www.iheart.com/live/4276/?autoplay=true
Date: December 5, 2013
Time: 3:15pm EST | 2:15pm CST | 12:15pm PST
Network: Clear Channel Network
Show: The Traders Network
Station: DFW 1190 AM
Host: Michael Yorba
About Clear Channel
Clear Channel Media and Entertainment’s more than 840 radio stations offer programming nationwide. Individual station brands connect with diverse audiences in local markets across the country. DFW1190AM.com Dallas-Ft. Worth, TX www.clearchannel.com.
About Michael Yorba
Michael Yorba – featured host of Clear Channels DFW 1190AM in Dallas-Ft.Worth. For the past six years he has been integrally involved with the media industry in various capacities including building an IPTV Network, developing, producing and hosting a daily one hour talk show called Commodity Classics and then later The Traders Network, defined as an audience empowered interactive financial program that has been broadcast live on internet television and radio. His focus has been on derivative portfolio analysis for individual and corporate clients through the use of futures and futures options, managed funds, and Forex.www.yorbamedia.com.
NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s research and development and clinical evaluation efforts as well as efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company’s ability to successfully grow its contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company’s periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
A CommPro Worldwide PR Event
PR & Media Contact:
Matt Bird, CEO
C: +1 (646) 401-4499
For more information visit: commpro.com | Twitter | LinkedIn | Facebook
Sorry, the comment form is closed at this time.